H
H. Zhang
Publications - 9
Citations - 1
H. Zhang is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 9 publications receiving 1 citations.
Papers
More filters
Journal ArticleDOI
P1192: asia subpopulation analysis from the phase iii polarix trial
Y. Song,Jie Jin,H. Tilly,H. Zhang,Lu Zhang,S. Rai,Hideto Goto,Yasuhito Terui,W.S. Kim,H.-J. Shin,Jyh-Pyng Gau,C.-H. Tsai,Jeff P. Sharman,Lilian Bu,Jamie Hirata,C.K. Lee,Koji Izutsu,J. Zhu +17 more
TL;DR: The results from the Asia subpopulation of POLARIX were consistent with the global study, with a clinically meaningful improvement in PFS following treatment with Pola-R-CHP vs R-CHOP, and a comparable safety profile in Asian patients with previously untreated DLBCL.
Journal ArticleDOI
Orelabrutinib‐lenalidomide‐rituximab (olr) in patients with untreated mantle cell lymphoma (mcl): a prospective, multicenter, single‐arm phase 2 polaris study in china
H. Zhang,Liping Su,L. Liu,Ou Bai,Zheng Song,Z. Zhao,Chong He,Qiang Guo,X. Wang,W Li,Lihua Qiu,L. Li,Yizhou Fei,Bin Meng +13 more
Journal ArticleDOI
[Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Jie Zha,Shuhua Yi,Z. Li,Lingyan Ping,X. H. He,Z Zheng,W. Xu,F L Chen,B Y Chen,H. Zhang,Li Wang,Ke Ding,W Y Li,H Y Yang,Liping Qiu,Z. Li,Y. Song,B. Xu +17 more
TL;DR: FL patients with DLBCL component ≥50% have more invasive clinical and pathological features and CHOP/CHOP like ± rituximab regimen can improve the clinical efficacy of patients.
Journal ArticleDOI
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (r/r cll) in china: a subgroup of alpine
Lugui Qiu,Keshu Zhou,T. Wang,Ling Pan,W. Xu,Jie Jin,W. Zhang,Y. Hu,J R Hu,Ru Feng,P Li,Z Liu,P. Liu,Hongmei Jing,Su-jun Gao,Kang Yu,Z. Wang,H. Zhang,X.D. Zhu,Dong Yan,Jie Weng,Lina Fu,Tommi Salmi,Ken Wu,L. Wang +24 more
TL;DR: Wang et al. as discussed by the authors compared Zanubrutinib with ibrutrinib as a treatment for R/R CLL (including small lymphocytic lymphoma [SLL) in a randomized phase 3 study (ALPINE; NCT03734016).
Journal ArticleDOI
Genetic and transcriptomic analyses of diffuse large B‐cell lymphoma patients with poor outcomes within two years of diagnosis
Weicheng Ren,Sulaf Abd Own,Hui Wan,Mattias Berglund,X. Wang,M. Yang,X Li,D. Liu,Kristina Sonnevi,Gunilla Enblad,Rose-Marie Amini,Birgit Sander,K. Wu,H. Zhang,Björn E. Wahlin,K. Smedby,Qiang Pan-Hammarström +16 more
TL;DR: Wang et al. as mentioned in this paper performed a comprehensive genomic and transcriptomic characterization on 161 R-CHOP-treated DLBCL samples and developed a prognosis model to identify those high-risk patients.